专利检索 ap:("ONCOC4, INC." OR "University of Maryland, Baltimore") AND inv:"Yan Zhang" 第 1 页

1.

发明授权
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects 有权

公开(公告)号：US12129299B2

公开(公告)日：2024-10-29

申请号：US16967079

申请日：2019-01-29

申请人： ONCOC4, INC. , University of Maryland, Baltimore

发明人： Yang Liu , Pan Zheng , Fei Tang , Mingyue Liu , Martin Devenport , Xuexiang Du , Yan Zhang

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 , C07K16/2827 , C07K2317/565 , C07K2317/71

摘要： This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

2.

发明申请
MUTANT ANTI-CTLA-4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT ATTENUATED ADVERSE EFFECTS 有权

公开(公告)号：US20210040212A1

公开(公告)日：2021-02-11

申请号：US16967079

申请日：2019-01-29

申请人： Oncolmmune, Inc. , University of Maryland, Baltimore

发明人： Yang Liu , Pan Zheng , Fei Tang , Mingyue Liu , Martin Devenport , Xuexiang Du , Yan Zhang

IPC分类号： C07K16/28

摘要： This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.